SURROZEN INC (SRZN)

Company Profile

Surrozen Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 74 full-time employees. The company went IPO on 2020-11-23. Surrozen, Inc. is a clinical-stage biotechnology company. The firm is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The firm's lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancers Engineered for Tissue Specificity (SWEETS), enable it to potently and selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. Its product candidates include SZN-1326, SZN-043 and SZN-413.

Company Info

SURROZEN INC

171 Oyster Point Blvd, Suite 400

South San Francisco CALIFORNIA

P: 16504752820

CEO: Gad Soffer

Employees: 74

Website: https://www.surrozen.com